Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

Enyo Pharma is a biopharmaceutical company that develops innovative ... non-bile acid NR1H4 agonist that treats alport syndrome; EYP651 targets chronic kidney disease and nonalcoholic steatohepatitis; ...

BAY-3283142 is under clinical development by Bayer and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure ... data points from various databases found on GlobalData’s ...

THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq ... in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication ...

Yunnan Baiyao Group Co. Ltd. A 0.55% ¥107B Tasly Pharmaceutical Group Co. Ltd. A 1.09% ¥21.97B Jiangsu Hengrui Medicine Co. Ltd. A-0.62% ¥293.66B Zhejiang Hisun Pharmaceutical Co. Ltd. A 0.36% ...

Sanofi and Regeneron are in the process of testing out blockbuster biologic Dupixent in the indication, for one, and clinical-stage biotechs Asana BioSciences and Afecta Pharmaceuticals are both ...